Seeking Alpha
Value, growth, long-term horizon, medium-term horizon
Profile| Send Message| ()  

Interested in the healthcare sector? Healthcare investments are known to be defensive - that is, they tend to perform well during times of recession. If you expect more trouble ahead for the financial markets, you may be interested in this list.

We ran a screen on the healthcare sector for stocks with current "Buy" ratings from Canaccord Genuity (analysts at Canaccord Genuity believe these stocks will outperform).

Interactive Chart: Press Play to compare changes in analyst ratings over the last two years for the top six stocks mentioned below. Analyst ratings sourced from Zacks Investment Research.‬

We also created a price-weighted index of the stocks mentioned below, and monitored the performance of the list relative to the S&P 500 index over the last month. To access a complete analysis of this list's recent performance, click here.

Do you think these stocks will perform well as analysts at Canaccord Genuity expect? Use this list as a starting point for your own analysis.

List sorted by ratings date.

1. NuVasive, Inc. (NUVA): Engages in the design, development, and marketing of minimally disruptive surgical products and procedures for the spine. Market cap of $657.68M. On 01/23/2012, Canaccord Genuity had a Buy rating on the stock. The stock has recently rebounded, and is currently trading 17.67% above its SMA20 and 18.95% above its SMA50. However, the stock still trades 30.77% below its SMA200. The stock has had a couple of great days, gaining 8.65% over the last week.

2. Impax Laboratories Inc. (IPXL): Engages in the development, manufacture, and marketing of bioequivalent pharmaceutical products. Market cap of $1.24B. On 01/09/2012, Canaccord Genuity had a Buy rating on the stock. The stock is a short squeeze candidate, with a short float at 5.86% (equivalent to 6.71 days of average volume). It's been a rough couple of days for the stock, losing 8% over the last week.

3. Exact Sciences Corporation (EXAS): Focuses on developing a molecular diagnostic screening technology for the early detection and prevention of colorectal pre-cancer and cancer. Market cap of $523.41M. On 01/06/2012, Canaccord Genuity had a Buy rating on the stock. The stock is a short squeeze candidate, with a short float at 12.4% (equivalent to 10.83 days of average volume). The stock has had a good month, gaining 15.74%.

4. Edwards Lifesciences Corp. (EW): Offers products and technologies designed to treat advanced cardiovascular disease worldwide. Market cap of $8.93B. On 12/12/2011, Canaccord Genuity had a Buy rating on the stock. The stock has had a good month, gaining 10.27%.

5. AngioDynamics Inc. (ANGO): Designs, develops, manufactures, and markets various therapeutic and diagnostic devices that enable interventional physicians to treat PVD, tumors, and other non-coronary diseases. Market cap of $353.19M. On 07/15/2011, Canaccord Genuity had a Buy rating on the stock. The stock has had a couple of great days, gaining 5.87% over the last week.

6. Raptor Pharmaceuticals Corp. (RPTP): Operates as a biotechnology company in the United States. Market cap of $308.12M. On 05/12/2011, Canaccord Genuity had a Buy rating on the stock. The stock is a short squeeze candidate, with a short float at 9.39% (equivalent to 9.92 days of average volume). The stock has gained 74.32% over the last year.

7. Meridian Bioscience Inc. (VIVO): Develops, sells, and distributes diagnostic test kits. Market cap of $748.51M. On 03/24/2011, Canaccord Genuity had a Buy rating on the stock. The stock is a short squeeze candidate, with a short float at 12.68% (equivalent to 21.87 days of average volume). It's been a rough couple of days for the stock, losing 9.79% over the last week.

8. Inhibitex, Inc. (INHX): Focuses on the development of differentiated anti-infective products to prevent or treat serious infections, primarily shingles and chronic infections caused by hepatitis C virus. Market cap of $2.01B. On 02/28/2011, Canaccord Genuity had a Buy rating on the stock. The stock has had a good month, gaining 135.25%.

*Ratings data sourced from Yahoo! Finance, all other data sourced from Finviz.

Source: Canaccord Genuity Rates These 8 Healthcare Stocks A Buy